Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-Reported Symptom Burden Among Thyroid Cancer Survivors: Retrospective Cohort Study.

JCO clinical cancer informatics·2026

Same author

Hypoparathyroidism Post Thyroidectomy: Prevention, Evaluation, Management, and Application of Recent Guidelines.

Thyroid : official journal of the American Thyroid Association·2026

Same author

Advancing Dry Electroencephalography With Scalable, Soft, and Transcranial Magnetic Stimulation-Compatible Ti<sub>3</sub>C<sub>2</sub>T<sub>x</sub> MXene Electrodes for Research and Clinical-Grade Applications.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Blood-Based Immunoglobulin-Bound Neoantigen Signatures Associated with MEN Type 1-Related Duodenopancreatic Neuroendocrine Tumor Progression.

Journal of the American College of Surgeons·2026

Same author

The shifting landscape of germline RET pathogenic variants with the introduction of panel testing.

Surgery·2025

Same author

Surgical management of metastatic adrenocortical carcinoma: Is there a role for multivisceral resection?

Surgery·2025

Same journal

Complete Response of Merkel Cell Carcinoma to Immunotherapy and Single-Fraction Radiotherapy Following Severe COVID-19 Infection: A Case Report and Review of Immune Mechanism.

The American surgeon·2026

Same journal

Perioperative Acute Myocardial Infarction in Non-Cardiac Operations: A National Analysis.

The American surgeon·2026

Same journal

Outcomes of Completion Cholecystectomy: Association With Patient Comorbidity in a National Database.

The American surgeon·2026

Same journal

Building the Conversation: Editorial Stewardship in Contemporary Surgical Publishing.

The American surgeon·2026

Same journal

Musculoskeletal Pain in Surgeons on Operating Days.

The American surgeon·2026

Same journal

Splenectomy During Cytoreductive Surgery: Marker of Surgical Burden or Independent Predictor of Morbidity?

The American surgeon·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 21, 2025

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

HER2 expression in thyroid tumors.

Matthew M Mondi¹, Ryan Rich, Phillip Ituarte

¹Department of Surgery, Wake Forest University Medical Center, Winston-Salem, North Carolina 27158, USA.

The American Surgeon

|January 1, 2004

Summary

This summary is machine-generated.

Human epidermal growth factor receptor 2 (HER2) is not significantly overexpressed in thyroid tumors. This study found no evidence of HER2 as a prognostic factor or therapeutic target in thyroid cancer.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Experiment Videos

Last Updated: Dec 21, 2025

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Area of Science:

Oncology
Molecular Biology
Endocrinology

Background:

Hormone receptor similarities exist between breast, prostate, and thyroid tumors.
Human epidermal growth factor receptor 2 (HER2) oncogene expression is established in breast and prostate tumors, but its presence in thyroid tumors is debated.
Conflicting data necessitate an investigation into HER2 expression in thyroid tissues.

Purpose of the Study:

To determine the incidence of HER2 overexpression in normal and malignant thyroid tissue.
To evaluate the potential of HER2 as a prognostic factor or therapeutic target in thyroid cancer.

Main Methods:

Immunohistochemical assay was used to analyze HER2 expression.
Normal and neoplastic thyroid tissue samples from 55 patients (46 female, 9 male) were examined.
Fluorescence in situ hybridization was employed for confirmatory testing.

Main Results:

Significant HER2 overexpression was not detected in any benign or malignant thyroid tissue samples.
Two male patients with thyroid carcinoma showed weak HER2 reactivity (1+) via immunohistochemistry, but were negative by fluorescence in situ hybridization.
No significant HER2 expression was observed in the evaluated thyroid tissues.

Conclusions:

The findings suggest that HER2 is not a significant factor in thyroid tumorigenesis.
HER2 is unlikely to be a valuable prognostic indicator for thyroid cancer.
Targeting HER2 may not be an effective therapeutic strategy for thyroid cancer.